Fri, 30 Oct 2026
09:15:11 am
Rudransh Sangwan
Published at: September 15, 2026, 5:30 AM
Synopsis
Tata Group stocks surged on September 15, led by Tata Chemicals, TCS and Tata Motors PV. Find out why the RBI decision on Tata Sons has put a potential IPO back in focus.

Tata Group stocks saw strong buying on Tuesday, September 15, with Tata Chemicals rising nearly 20% and TCS gaining as much as 5.5%.
Loading chart...
Tata Motors Passenger Vehicles also climbed around 5%, while Tata Power, Indian Hotels, Tata Consumer Products and other group stocks traded higher.
The buying came after reports that the RBI rejected Tata Sons' application to surrender its Core Investment Company registration.
| Tata Group stock | Intraday gain |
|---|---|
| Tata Chemicals | 20% |
| TCS | 5.5% |
| Tata Motors PV | 5% |
| Tata Power | 1.5% |
| Indian Hotels | 1.2% |
| Tata Consumer Products | 1.2% |
| Voltas | 0.95% |
| Tata Steel | 0.3% |
| Trent | 0.15% |
TCS was among the top gainers in the Nifty 50. The stock rose as much as 5.5% to an intraday high of ₹2,322.
Loading chart...
Tata Chemicals was the biggest mover among the listed Tata Group stocks, climbing close to 20% during the session.
The buying interest followed reports that the Reserve Bank of India rejected Tata Sons' request to surrender its Core Investment Company registration.
The decision could keep Tata Sons within the regulatory framework that requires it to pursue a stock market listing.
This has once again brought the possibility of a Tata Sons IPO and public listing into focus.
Tata Group companies have also remained in focus amid discussions around the group's funding requirements.
Tata Sons is the main holding company of the Tata Group.
It holds significant stakes in businesses across IT, automobiles, steel, consumer products, aviation, hospitality and financial services.
A public listing would bring greater disclosure around Tata Sons' financial position, investments and capital allocation.
The Tata Group has continued to attract investor attention because of its presence across multiple business sectors.
The issue dates back to the RBI's scale based regulatory framework introduced in 2021.
In September 2022, Tata Sons was placed in the Upper Layer category for NBFCs. Companies in this category face stricter regulatory requirements, including a stock market listing requirement.
Tata Sons sought to surrender its Core Investment Company registration to avoid remaining under the NBFC framework.
The company also repaid more than ₹21,000 crore of debt in 2024 and became debt free.
The RBI has continued to remain a key regulatory focus for financial markets.
The possible listing has faced resistance from Tata Trusts, which owns more than 65% of Tata Sons.
The Shapoorji Pallonji Group, which owns roughly 18%, has supported a listing, arguing that it could help shareholders realise value from their stake.
The RBI's latest decision could bring this long running issue back into focus.
The Tata stocks have previously reacted to developments surrounding Tata Sons and its leadership.
Tata Group stocks outperformed the broader market during the morning session.
| Index | Gain at 9:38 am |
|---|---|
| Nifty Tata 25 Cap | 1.4% |
| Nifty 50 | 0.12% |
The next focus will be on Tata Sons' response to the RBI decision and the steps that follow regarding its regulatory status and possible stock market listing.
TCS has also featured prominently in broader market movements, while Tata Motors remains one of the major Tata Group stocks tracked by investors.

Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.

Motilal Oswal Q2 FY27 results show net profit rising 198% to ₹1,080 crore, revenue increasing 64% to ₹3,040 crore and EBITDA margin reaching 60.37%.

Bliss GVS Pharma Q2 FY27 results show revenue rising 37.3% to ₹261.13 crore, EBITDA jumping 161.4% and net profit increasing 196%.

Alivus Life Sciences Q2 FY27 results show net profit rising 51.3% to ₹196.8 crore, revenue growing 16% to ₹682 crore and EBITDA margin reaching 38.

Thyrocare Q2 FY27 revenue rose 25.1% to ₹270.81 crore, while net profit fell 66.9% to ₹15.89 crore amid a ₹44.98 crore impairment loss.

Patel Retail will invest ₹2 crore to add 20,000 sq ft to its Ambernath distribution centre, increasing covered area to 84,000 sq ft.